Imperial Blue integration nears March 2027; margin targets 16–18%

Tilaknagar Industries Limited (TI) — Q4 FY26 & FY26 Earnings Call (held May 30, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly highlights “impressive performance,” “record volumes,” and “incredibly excited about opportunities.”
• Confidence is shown in integration completion (“transitioned by end of FY27”) and margin trajectory (“EBITDA margin of 16%-18%… over the next 24 to 36 months”).
• Even when acknowledging risks (geopolitical input cost pressure, TSMA disruptions), responses emphasize mitigation actions and delivery (“team has done a commendable job”).

2. Key Themes from Management Commentary

• Imperial Blue integration progress (TSMA exit + operational transition):
• “75% of the IB business has exited TSMA till Q4 FY26.”
• Remaining TSMA states: “only 3 states remain… outer date of March-27.”
• Early April disruptions acknowledged, but “record volumes in the month of May for Imperial Blue under TI ownership.”
• Strong volume momentum post-acquisition:
• FY26 volumes: “almost 20 million cases… with only 4 months of Imperial Blue.”
• FY26 overall volumes: “increased by 68%.”
• Q4 overall volumes: “increased by 135%… crossing 8 million cases,” with IB “4.6 million cases.”
• Premiumization + luxury expansion via distribution strength:
• “Dual engine” strategy: existing portfolio + “robust NPD pipeline.”
• Spaceman Spirits Lab partnership used to “capture the market through targeted luxury launches.”
• Margin strategy anchored in operating leverage + cost optimization:
• Focus areas explicitly include packaging/process/supply chain optimization and operating leverage.
• Margin guidance reiterated despite geopolitical input cost pressure.
• Balance sheet / deleveraging discipline:
• Net debt-to-EBITDA target: “below 1.0x by FY29.”
• Working capital cycle guided (gross revenue days).
• Capacity expansion for supply security (Prag, Andhra):
• Capacity from “6 lakh… to 36 lakh cases per annum.”
• Expected bottling cost savings: “INR 10 crore per annum.”
• Investment: “around INR 59 crore… fully invested.”
• Accounting/disclosure change affecting reported revenue & gross margin:
• Selling expenses previously in “Other Expenses” now shown as “reduction from gross revenue.”
• Management states: “negative impact on reported revenue and gross margins,” but “no impact on absolute EBITDA, PAT or EPS.”

3. Q&A Analysis

Theme A: Imperial Blue performance drivers (seasonality, run-rate, volume growth)

• Core questions
• Why ex-IB volume growth was “flattish” in Q4?
• IB seasonality: strongest/weakest quarters?
• IB run-rate and how Maharashtra/Karnataka impacts near-term growth.
• Management responses
• Ex-IB Q4 flattish: Q4 FY25 Andhra was unusually high due to “route to market change… October/November 2024.”
• IB seasonality: “slightly more equally distributed,” with “H2… around 52% of the volumes.”
• IB growth outlook: Maharashtra impact largely “already set in the base of FY26,” expecting similar or better growth; IB “potentially will grow slightly faster… on account of a lower base.”
• Notable / evasive elements
• NSR brand-wise segregation declined: “we are not giving an NSR segregation on a brand-wise basis.”
• Remaining TSMA states not disclosed: “We will not disclose that.”

Theme B: Margins—what drives expansion (custom duty/UK FTA vs operational initiatives)

• Core questions
• How much of margin expansion comes from scotch import/custom duty vs operational initiatives?
• Path to 16%-18% from current ~14%-15%.
• Whether guidance assumes sustaining margins under RM inflation/geopolitical tensions.
• Management responses
• Duty/customs benefit: “majorly towards Imperial Blue… margin benefit… 60-100 bps” on combined basis.
• Path to 16%-18%: Q4 already “15.5%” and FY26 “15.5%”; lower end assumes geopolitical inflation “taken care of… lower range.”
• Short-term caveat: Q1 may see “some level of short-term impact” but full-year guidance should hold.
• Strong/clear answers
• Explicit quantification of duty-related impact (60–100 bps) is relatively specific.

Theme C: Integration timeline, TSMA costs, and any further Imperial Blue costs

• Core questions
• When will TSMA fully transition? Any delays beyond FY27?
• TSMA charges timeline and how they flow through P&L.
• Any further Imperial Blue-related costs?
• Management responses
• Transition: “outer date of March-27” (earlier) and later “transitioned by end of FY27… I do not see any reason for… delays.”
• TSMA fees: “decreasing quarter-on-quarter,” full-year impact “anywhere between INR 55 crore to INR 60 crore.”
• Further costs: deferred consideration “EUR 28 million… after 4 years,” otherwise “no other costs… to be incurred.”
• P&L treatment: TSMA fees described as “extraordinary items… not show up… apart from a really small component of maybe 5%.”
• Evasive/partial
• Remaining TSMA states not disclosed; also no detailed breakdown of NSR by brand.

Theme D: Accounting/disclosure change impact (NSR, revenue, gross margin)

• Core questions
• NSR for IB under new accounting treatment; reconciliation vs prior Q3 numbers.
• How to interpret revenue run-rate estimates given accounting changes.
• Management responses
• IB NSR not separately provided; approximate adjustment: “under the new net of selling expenses… approximately INR 20 to INR 30 above… existing combined NSR.”
• Run-rate/revenue: acknowledged need to “change the NSR per case assumption” due to accounting.
• Revenue > INR 5,000 crore discussion: management attributes differences to “change in accounting” and selling-cost deduction.
• Notable
• Management repeatedly points to accounting changes as the reason for mismatches—this is consistent but also limits comparability.

Theme E: Other strategic questions (portfolio launches, vodka, Nigeria investment, Telangana dues)

• Core questions
• New launches (vodka, brandy penetration beyond South, luxury whiskey timing).
• Nigeria investment rationale and addressable volume.
• Telangana dues: stability and collection efforts.
• Management responses
• Vodka: no new vodka brand; “Amara Vodka” expected to show traction via usership.
• Launch timing: luxury whiskey “launched in this quarter” (from Q&A context); NPD pipeline details “premature” at times.
• Nigeria: existing “around 2.5 lakh cases” business; investment up to “INR 30 crore.”
• Telangana dues: “stable… no deterioration since January,” actively working to reduce outstanding days.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Volume growth
• FY27 (combined business): “high-single digit to low-double digit volume growth.”
• “Double-digit volume CAGR over the next 3 years.”
• Margins
• Consolidated EBITDA margin: “16%-18%… over the next 24 to 36 months.”
• FY26 base: EBITDA margin “15.5%” (stated in Q&A as guidance base).
• Deleveraging
• Net debt-to-EBITDA: “below 1.0x by FY29.”
• Capex
• Maintenance capex: “approximately INR 25 crore in each of the years” (FY27 and FY28).
• Working capital
• Working capital cycle: “53 to 55 days of gross revenue.”
• TSMA fees
• Full-year impact: “INR 55 crore to INR 60 crore” (as TSMA exits progress).

Implicit signals (qualitative)

• Integration confidence: “transitioned by end of FY27… no reason… delays.”
• Cost pressure acknowledged: geopolitical scenario may pressure input costs/margins, but mitigations are “identified and… working on.”
• Revenue comparability caution: accounting change will distort reported revenue/gross margin, but EBITDA/PAT/EPS are unaffected.

5. Standout Statements (direct / high-signal)

• Integration delivery
• “75% of the IB business has exited TSMA till Q4 FY26.”
• “We expect to transition them… with an outer date of March-27.”
• “We would be transitioned by end of FY27… I do not see any reason for any kind of delays.”
• Margin framework
• “EBITDA margin of 16%-18%… over the next 24 to 36 months.”
• “Any reduction in custom duty… margin benefit… 60-100 bps… majorly towards Imperial Blue.”
• “Q4… we have already done 15.5%… For the whole of FY26, we have done 15.5%.”
• Accounting change
• “This change will have a negative impact on reported revenue and gross margins… but… no impact on absolute EBITDA, PAT or… EPS.”
• Capacity economics
• “Expect savings in bottling costs… INR 10 crore per annum.”
• Geopolitical risk handling
• “we do expect some pressure on the input costs and margins… cost optimizations… will mitigate.”

6. Red Flags / Positive Signals

Red flags
– Comparability risk due to accounting change: repeated reliance on “change in accounting” to explain revenue/NSR mismatches (limits external validation).
– Disclosure constraints: refusal to disclose remaining TSMA states and brand-wise NSR.
– Margin guidance depends on mitigation: geopolitical pressure acknowledged; short-term margin impact possible (“You may see some level of short-term impact” in Q1).

Positive signals
– Integration execution credibility: despite TSMA disruptions in early April, management cites “record volumes… in May.”
– Clear quantitative margin attribution: duty/customs benefit quantified (60–100 bps).
– Operational levers identified: packaging/process/supply chain + operating leverage + bottling cost savings.

7. Historical Comparison & Consistency Analysis (vs prior calls)

a. Change in Tone Over Time

• Q1 FY26 (Aug 2025): confident on demand and premiumization; acquisition still pending; less operational detail.
• Q2 FY26 (Nov 2025): optimistic but “once Imperial Blue deal closure is achieved, we will come back with revised margin guidance.”
• Q3 FY26 (Feb 2026): integration underway; guided margin expansion for combined business (250–350 bps on acquired business over 24 months).
• Q4 FY26 (May 2026): tone becomes more execution-focused and confident:
• TSMA exit progress quantified (75% exited).
• Integration timeline tightened (“end of FY27”).
• Margin guidance reiterated with a stated base (15.5% FY26).
• Classification: More Optimistic (more delivery evidence + tighter timelines + clearer margin base).

b. Tracking Past Commitments vs Outcomes

• TSMA exit by Q4 FY26
• Past statement (Q3 FY26): “phase-wise exit… aim of getting significant operations under TI belt by Q4 FY26.”
• Current outcome: “75% of the IB business has exited TSMA till Q4 FY26.” ✅ Delivered (partially quantified)
• Prag capacity commissioning
• Past statement (Q3 FY26): expanded facility “commissioned in the 4th quarter of the current fiscal.”
• Current outcome (Q4 FY26): government nod for expanded capacity; capacity increased to “36 lakh cases per annum”; investment “fully invested.” ✅ Delivered (operationally validated)
• Margin expansion on acquired business (250–350 bps)
• Past statement (Q3 FY26): “margin expansion by 250 – 350 bps on the acquired business over the next 24 months.”
• Current outcome: guidance now framed as consolidated EBITDA margin “16%-18%” and duty benefit “60-100 bps”; management also states FY26 base 15.5% and expects improvement within range. ✅ On track (directionally), but less directly comparable due to accounting change
• IB integration completion
• Past statement (Q3 FY26): TSMA exit “outer date of March-27” (implied transition over next few quarters).
• Current statement: “transitioned by end of FY27… no reason… delays.” ✅ Improving confidence / tightened expectation

c. Narrative Shifts

• From “deal pending” → “integration execution”: early calls emphasized acquisition rationale and confidentiality; now focus is on TSMA exit, operational disruptions, and run-rate.
• Margin narrative shifted from “expansion math” to “accounting + mitigation”:
• Q3 emphasized margin expansion bps.
• Q4 adds a major disclosure/revenue recognition change that affects gross margin comparability.
• Portfolio narrative broadened: luxury and Spaceman synergies become more central; new brand launch details sometimes “premature,” but luxury whiskey timing is now provided.

d. Consistency & Credibility Signals

• Credibility: Medium to High
• Strength: integration milestones are quantified and timelines are reiterated.
• Weakness: accounting/disclosure change repeatedly used to reconcile revenue/NSR expectations; brand-wise NSR and some TSMA details remain undisclosed.

e. Evolution of Key Themes

• Demand/volumes: consistently strong growth trajectory; Q4 shows acceleration (Q4 overall volumes +135% YoY).
• Margins: guidance remains stable (16%-18%), but short-term pressure acknowledged; FY26 base margin explicitly stated (15.5%).
• Integration risk: acknowledged early disruptions; risk narrative has reduced as TSMA exit progressed.
• Policy/macro: excise policy changes in states remain a key driver; geopolitical input cost pressure introduced as a new explicit risk in Q4.

f. Additional Insights (cross-period)

• Accounting change is now a recurring “explanation lever”: multiple Q&A answers cite “change in accounting” for NSR/revenue run-rate discrepancies—this can mask underlying performance variability.
• TSMA disruption risk appears “contained” but not eliminated: early April disruptions acknowledged; management’s proof point is May volumes—however, no detailed quarter-by-quarter recovery path is provided.